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ALLELIC LOSS OF CHROMOSOME lp  AS A PREDICTOR OF UNFAVORABLE OUTCOME IN  
PATIENTS W ITH NEUROBLASTOMA
H u m  C a r o n ,  M.D., P h .D .,  P e te r  v an  S lu is , J a n  de K r a k e r ,  M.D., Ph .D., J o s  B ö k k e r in k , M.D., P h .D .,
M a a r t e n  E g e le r ,  M.D., Ph .D., G enev iève  L au reys , M.D., Ph .D., R o s a ly n  S la t e r ,  Ph .D., 
A n d r ie s  W e s te r v e ld ,  Ph .D., PA . V o û te ,  M .D .,  Ph .D., and  R o g ie r  V ers teeg , Ph .D.
Abstract Background. Neuroblastoma is a childhood 
tumor derived from cells of the neural crest, with a widely 
variable outcome. Differences in the behavior and prog­
nosis of the tumor suggest that neuroblastoma can be di­
vided into several biologic subgroups. We evaluated the 
most frequent genetic abnormalities in neuroblastoma to 
determine their prognostic value.
Methods. We used Southern blot analysis to study 
the allelic loss of chromosomes 1p, 4p, 11 q, and 14q, the 
duplication of chromosome 17q, and the amplification of 
the N-myc oncogene in 89 neuroblastomas. We also de­
termined the nuclear DNA content of the tumor cells.
Results. Allelic loss of chromosome 1 p, N~myc ampli­
fication, and extra copies of chromosome 17q were sig­
nificantly associated with unfavorable outcomes. In a 
multivariate analysis, loss of chromosome 1p was the 
most powerful prognostic factor. It provided strong prog­
nostic information when it was included in multivariate
models containing the prognostic factors of age and 
stage or serum ferritin level and stage. Among the patients 
with stage I, II, or IVS disease, the mean (±SD) three-year 
event-free survival was 100 percent in those without al­
lelic loss of chromosome 1p and 34±15 percent in those 
with such loss; the rates of three-year event-free survival 
among the patients with stage III and stage IV disease 
were 53±10 percent and 0 percent, respectively.
Conclusions. The loss of chromosome 1p is a strong 
prognostic factor in patients with neuroblastoma, inde­
pendently of age and stage, it reliably identifies patients 
at high risk in stages I, N, and IVS, which are otherwise 
clinically favorable. More intensive therapy may be con­
sidered in these patients. Patients in stages III and IV 
with allelic loss of chromosome 1p have a very poor out­
look, whereas those without such loss are at moderate 
risk. (N Engl J Med 1996;334:225-30.)
©1996, Massachusetts Medical Society.
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EUROBLASTOMA is a childhood cancer that
originates in cells of the neural crest. The clinical 
course of the disease varies widely.' Patients with lo­
calized neuroblastoma (those in stages I and II) have 
a good prognosis after surgical resection, whereas the 
majority of patients with stage III or IV neuroblasto­
ma have an adverse outcome despite intensive multi­
modal therapy. However, disseminated stage IVS neu­
roblastomas (those that would be classified as stage
1 or II but for the presence of remote disease confined 
to the liver, skin, bone marrow, or a combination of 
these, without, radiographically detectable bone me- 
lastases) frequently undergo spontaneous regression. 
Factors such as age, tumor stage, tumor histology, and 
serum levels of lactate dehydrogenase (LDH) and fer­
ritin are clinically meaningful but imperfect predic­
tors of out come.~'(l Some patients in stages I, II, and 
IVS die from progressive disease, for example, where­
as a minority of those in stages III and IV can be 
cured.
Several nonrandom genetic abnormalities have been 
identified in patients with neuroblastoma. These include 
allelic loss of chromosomes lp,7*11 4p (unpublished da-
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ta), llq ,11 and 14q37,11,12 indicating loss of function of as 
yet unknown tumor-suppressor genes contained in diosc 
regions. Furthermore, there maybe amplification of die 
N-myc oncogene11'15 and additional copies of part of the 
long arm of chromosome 17 (17q).10,17 It has been estab­
lished that amplification of the N-myc oncogene has a 
strongly unfavorable prognostic value.14,1’5 A nearly dip­
loid nuclear DNA content has also been shown to corre­
late with a poor response to chemotherapy and an unfa­
vorable outcome, especially in patients under the age of 
two years at diagnosis.11*18 In some series, allelic loss of 
chromosome has been associated with a poor
outcome, but these results are based on the study of a 
limited number of patients. The prognostic value of the 
other genetic abnormalities has not yet been studied in 
detail. In this study we attempted to estimate the prog­
nostic value of all well-established genetic abnormal­
ities in patients with neuroblastoma.
M e t h o d s
Patients and Collection of Samples
We obtained samples of tumor tissue and blood from 101 patients 
with neuroblastoma. From 1990 through 1994, 77 samples were col­
lected prospectively from the Emma Kinderziekenhuis-Academic 
Medical Center, die Center of Pediatric Oncology of the Southeastern 
Netherlands, and the Sophia Kindcrzickcnhuis (all in the Nether­
lands) and the University Hospital of Ghent (in Belgium). T he study 
methods were approved by the institutional review board. The tumor 
samples were snap-frozen in the operating room and stored at 
— 80°C. A further 21 tumor and control samples from the years 1984 
through 1990 wen' obtained retrospectively from the tissue bank of 
the Emma Kinderziekenhius-Academic Medical Center. The sam­
ples from eight patients were excluded, beeause less than GO percent 
of the tumor cells they contained were histologically recognizable. 
The status of chromosome Ip could not be assessed in four patients.
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The group of patients described in tins paper thus consisted of the 
remaining 89 patients.
Clinical Characteristics
All the patients were classified according to the Evans staging sys­
tem,21 with conventional imaging techniques, nietaiodobcnzylguarii- 
dine (MIBG) scanning, and examination of bone marrow aspirates 
and biopsy specimens obtained with a trephine. The patients’ ages 
at diagnosis were recorded. Serum ferritin and LDH levels at diag­
nosis were determined by routine laboratory procedures, with the 
upper limits of the normal range defined as described elsewhere.2'* 
For the serum ferritin level the upper limit was 142¿/.g per liter,-1 and 
for serum LDH  it was 1500 U per liter.2,5 The treatment of stage I 
and II tumors consisted of surgical resection, followed by chemother­
apy only if (here was gross residual disease. Stage III and IV  tumors 
were treated with various chemotherapeutic regimens, all of which 
contained at least an alkylating agent, a platinum derivative, and 
vinca alkaloids. From 1990 onward, MIBG labeled with iodine-131 
was used in the first-line treatment of uriresectable stage III or IV  
tumors. Patients with stage IVS tumors were treated only if they had 
life-threatening symptoms or when there were signs of tumor pro­
gression.
Genetic Analysis
Extraction of high-molecular-weight DNA, digestion with appro­
priate endonucleases, Southern blot analysis, and hybridization with 
DNA probes were performed as described elsewhere.H The number 
of copies of N-wyc per haploid genome was determined by densito- 
mctric analysis of filters hybridized with a probe for exon 2 of N-wyc 
(pNbI),:* and a control probe, as described elsewhere.8 In the genetic 
analysis of chromosome ip, we used the following combinations of pol­
ymorphic probes and enzymes: CEB15 and Taql at locus D IS  172 and 
MSI or MUcl and Taql at locus D1S7. In the analysis of chromosome 
4p we used I-I5.52 and Mspl at D4S10, p 157.9 and Psil at D4S111, 
pYNZ32 and Taql at D4S125, and GEB61 and Taql at D4S1100. To 
study chromosome 1 lq we used pMCT28.1 andAfr/)I at DHS144 and 
SS6 and Taql at INT2. To study chromosome 14q we used pAWlOl 
and EcoWl plus Taql at D H S l, pMLJ 14 and Taql at D14S13, cKKA39 
and Taql at D14S23, and pAT6.5 and/lwzll plus Taql at PI. Loss of an 
allele at an informative locus was examined by densitometrie analy-
Table 2. Genetic Findings According to Chro­
mosome 1 p Status in Samples of Tumor Tis­
sue from 89 Patients with Neuroblastoma.
Table 1. Clinical Characteristics of 89 Pa­
tients with Neuroblastoma, According to 
Chromosome 1p Status.
Characteristic and
No Loss
OF Ip Loss or lp
Catkgory* (N = 60) (N «  29) P Value!
no. o f patients (%)$
Stage
I, II, or IVS 27 (45) 10(34) 0.48
111 or IV 33 (55) 19(66)
Age
<1 yr 25 (42) 12(41) 0.84
>1 yr 35‘{58) 17 (59)
Ferritin
142 /¿g/liter 36 (71) 10(37) 0.008
>142 ¿¿g/Iiter 15 (29) 17(63)
Not evaluated 9 2
LDH
=^1500 U/liter 55 (95) 21 (72) 0.005
>  1500 U/Uter 3(5) 8(28)
Not evaluated 2 ,m i •
*Missing patients and patients who were not able to be eval­
uated for a given characteristic are shown as “not evaluated.”
tB y  the chi-square test, or by a two-Uuled Fisher’s exact test 
when one of the values being compared was less than 5.
¿Percentages shown are o f  all patients who could be evaluat­
ed with respect to the characteristic indicated.
V aiuahi.i; ano
No Loss 
oi Ip Loss or 1 p P
C ategory* (N - 60) (N ™ 2li) V ai u ri '
no. o f  patients ( ‘/r ) t
Chromosome 4p
No loss 41 (75) 19 (83) 0.63
Loss 14 (25) 4(17)
Not evaluated 5 6
Chromosome 1 lq
No loss 31 (79) 15(79) 0.61
Loss 8 (21) 4(21)
Not evaluated 21 10
Chromosome 14q
No loss 40 (82) 16 (73) 0.53
Loss 9(18) 6 (27)
Not evaluated 11 7
Chromosome 17t)
No gain 36 (72) 7 (29) 0.001
Gain 14 (28) 17(71)
Not evaluated 10 5
N-w.yc
1 copy only 60(100) 12(41) <0.001
>1 copy 0 17 (59)
Ploidy
Nearly diploid 26 (46) 19 (76) 0.019
Aneuploid 31 (54) 6 (24)
Not evaluated 3 4
"‘Patients who were not able to be evaluated for a pi von vari­
able are shown as "not evaluated."
fB y  the chi*si|uare test, o r  by a two-tailed Fisher's exact test 
when one of the values being com pared  was less than 5.
¿Percentages shown are o f  all patients who could be evaluated 
with respect to the variable indicated.
sis, as described elsewhere." To determine whether additional copies 
of the long arm of chromosome 17 were present, we list'd GMMlUi 
and Taql at locus U17S74, THH59 and Taql at DI7S4, and RMU:t 
and Taql at D17S24, following the same densilomcirio procedure. We 
determined nuclear DNA content by analyzing propidium iodine 
stained suspensions of tumor nuclei, with fluorescencc-activated cell 
sorting, using a modification of the method of Hedlev et al,'-
Statistical Analysis
The statistical end points in our analyses were evenl-frer survival 
and overall survival. The events we studied were the recurrence of 
disease after the attainment of complete remission and die progres­
sion of disease during therapy. We calculated univariate hazard ratio* 
with 95 percent confidence intervals, using the Cox proporlional-ha/- 
ards model.2-* The simultaneous prognostic el'leel of various factors 
was determined in a multivariate analysis with the Cos proportioual- 
hazards model.'" The probability of event-free survival was plolled 
over time according to specific prognostic factors with Kaplau-MHer 
life tables.24 Differences between groups in event-free survival were 
tested with log-rank statistics.
R e s u l t s
Characteristics of the Patients
Table 1 shows the clinical characteristics oi‘ the W) 
patients and the association of these leal tires with l hr 
allelic loss of chromosome lp. Fifty-two palienLs (f>B 
percent) had stage III or IV  neuroblastoma, and 37 pa­
tients (42 percent) had localized or stage IVS dissemi­
nated tumors. Thirty-seven patients (412 percent) wen* 
less than one year old at diagnosis. Thirty-two of’ 7<u> pa-
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Figure 1. Autoradiographs Showing Allelic Loss of Chromosome
1 p in a Neuroblastoma Specimen.
The distribution of alleles at two loci in tumor tissue (T) and nor­
mal tissue (N) is shown as detected by a TaqI probe.
tients tested (41 percent) had elevated serum ferritin 
levels, and 11 of 87 patients tested (13 percent) had se­
rum LDH levels over 1500 U per titer.
Genetic Analysis
We used Southern blot analysis to study allelic loss 
or gain in several chromosomal regions (i.e., Ip, 4p, 
llq , 14q, and 17q) and determine the presence or ab­
sence of N-myc amplification. The principal findings 
and their associations with the allelic loss of chromo­
some lp are shown in Table 2. Allelic loss of chromo­
some lp was found in 29 of the 89 patients (33 percent; 
an example of such loss is shown in Fig. 1). Allelic loss 
of chromosome lp was independent of the patient’s 
age or tumor stage but correlated significantly with 
increased serum levels of ferritin or LDH (Table 1). 
N-myc amplification was demonstrated in 17 of the 89 
tumor samples (19 percent) (Table 2). All the patients 
with N-myc amplification also had allelic loss of chro­
mosome lp. Thirty-one of 74 patients for whom there 
were data (42 percent) were found to have one or more 
additional copies of chromosome 17q. These chromo­
somal gains occurred significantly more often in the 
patienLs with allelic ioss of chromosome lp. There 
were allelic losses of chromosome 4p in 18 of 78 pa­
tients for whom data were available (23 percent), of 
chromosome llq  in 12 of 58 patients (21 percent), and 
of chromosome 14q in 15 of 71 patients (21 percent). 
None of these changes were significantly associated 
with allelic loss of chromosome lp or any other genetic 
variables studied. Furthermore, allelic loss of chromo­
some 4p, llq , or 14q and duplication of chromosome 
17q were not significantly correlated with age, tumor 
stage, or serum level of ferritin or LDH. A nuclear 
DNA content in the normal range (i.e., indicating a 
nearly diploid tumor) was found in 55 percent of the 
tumors studied, and a higher (i.e., aneuploid) DNA 
content in 45 percent. Significantly more of the pa­
tients with nearly diploid tumors had N-/?zyc amplifi­
cation, allelic loss of chromosome lp, and extra copies 
of chromosome 17q. Nearly diploid DNA content was
also found significantly more often in stage III and IV 
tumors.
Relation of Clinical and Genetic Factors to Outcome
We analyzed the ability of the various clinical and 
genetic factors to predict clinical outcome. The analy­
ses of event-free survival and overall survival yielded 
similar results, reflecting the very small possibility of a 
favorable outcome in patients with recurrent neuroblas­
toma. We therefore report the results of the analysis of 
event-free survival, because that end point reflects tu­
mor behavior more directly than does overall survival. 
The mean period of follow-up for the entire group of 
patients was 40 months.
We calculated univariate hazard ratios with the pro- 
portional-hazards model (Table 3). In this analysis, all 
four clinical variables studied had significant prognos­
tic value. Among the genetic variables, allelic loss of 
chromosome 4p, llq , or 14q had no prognostic value. 
Allelic loss of chromosome lp and amplification
were each associated with a high likelihood of an un­
favorable outcome. In addition, extra copies of chro­
mosome 17q and, to a lesser extent, nearly diploid nu­
clear DNA content were each associated with a bad 
prognosis.
Multivariate Analysis
Several genetic and clinical factors with significant 
prognostic value were interrelated in their ability to 
predict clinical outcome (Tables 1 and 2). To identify 
the most powerful prognostic factors, we performed 
multivariate analyses with the Cox proportional-haz- 
ards model. The hazard ratios calculated with two 
models using clinical variables are shown in Table 4. 
The first model contained age and tumor stage, the 
prognostic factors in widest use. The second model 
contained tumor stage and serum ferritin level, because 
that combination gave the best fit attainable with any
Table 3. Hazard Ratios Associated with Individual Genetic and 
Clinical Prognostic Factors in 89 Patients with Neuroblastoma.
V ariarle C ategories  C om pared*
H azard  R atio 
(95% C onfidence  
In te r v a l) P VALUEt
Clinical factors
Si age III or IV vs. I, II, or IVS 5.6 (2.3-13.4) <0.001
Age ^1  vs. <1 yr 3.7 (1.7-8.0) 0 .001
Ferritin >142 vs. ^142  /xg/liter 6.4 (3.0 - 13.7) <0.001
LDH >1500 vs. *51500 U/liter 4.6 (2.1-9.9) <0.001
«
Genetic factors
N-invc
»
>1 copy vs. 1 copy 6.8 (3.5-13.4) <0 .00 i
Chromosome Ip Loss vs. no loss 6.7 (3.4—13.3) <0.001
Chromosome 4p Loss vs. no loss 0.8 (0.3-2.0) 0.39
Chromosome l lq Loss vs. no loss 1.2 (0.5-2.7) 0.98
Chromosome 14q Loss vs. no loss 1.1 (0.5-2.4) 0.75
Chromosome 17q Gain vs. no gain 3.4 (1.7-6.8) <0.001
Ploidy Nearly diploid vs. aneuploid 2.2 (L I-4.6) 0.031
*For each variable, ihe prognostic significance o f  the first category listed was assessed by 
com paring that category with the reference category (the second category listed).
fF o r  the com parison o f  the hazard ratio shown with a hazard ratio o f  1.0 (as postulated by 
the null hypothesis).
w
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Table 4. Hazard Ratios Associated with Clinical and Genetic 
Prognostic Factors in a Multivariate Analysis of 89 Patients with 
Neuroblastoma, Using Cox Proportional-Hazards Models.
H azard R atio 
(9 5 i f  C onfidence
V awaull and Model C ategories C ompared* Interval) P Value '
Clinical factors
First model
Stage III or IV vs. I, II, or IVS 4.0(1.6-10.3) 0.003
Age vs. <1 yr 2.2 (0.9-5.0) 0.07
Second model
Stage III or IV vs. I, II, or IVS 2.6 (1.0-6.5) 0.043
Ferritin >142 vs. =5142 ¿ig/liter 4.9 (2.2-11.0) <0.001
Genetic factors added
Second model
Stage III or IV vs. I, ir, or IVS 2.6 (1.0-6,9) 0.062
Ferritin >142 vs. «142 Mg/liter 2.9(1.2-6.7) 0.015
>  1 copy vs. I copy 1.0 (0.4-2.8) 0.94
Chromosome Ip Loss vs. no loss 4.4(1.6-11.8) 0.004
*For each variable, the prognostic significance of the first category listed was assessed by 
comparing that category with the reference category (the second category listed).
fFor the comparison o f  the hazard ratio shown with a hazard ratio o f  1.0 (as postulated by 
the null hypothesis).
combination of the four clinical prognostic factors. 
Adding age or serum LDH level to the second model 
yielded no additional prognostic information, an indi­
cation that serum ferritin levels correlate with age but 
provide more prognostic information.
To test whether including any of the genetic factors 
would add prognostic information, we included each 
one in both models (data not shown), N-myc status and 
chromosome lp status each contributed significant prog­
nostic information to both models. When we added the 
presence of extra copies of chromosome 17q to both 
models, we obtained some additional prognostic infor­
mation, but this effect disappeared when either allelic 
loss of chromosome Ip or N-myc amplification was sub­
sequently added to the model. Nearly diploid nuclear 
DNA content provided no significant prognostic infor­
mation when that factor was added to either model, in­
dicating that the prognostic value it demonstrated on 
univariate analysis was redundant with the prognostic 
value of the clinical factors.
Superior Prognostic Value of Allelic Loss of
Chromosome 1p
We performed further multivariate analyses to ex­
plore the prognostic value of the allelic loss of chro­
mosome lp relative to that of N-myc amplification. The 
simultaneous addition of chromosome lp status and 
N-/W status to the second Cox model showed that lp 
status had the strongest predictive power when tested 
together with the other three factors (Table 4). When 
combined with loss of chromosome lp, N-myc amplifi­
cation lost its prognostic power. This indicates that 
allelic loss of chromosome lp is superior to N-m^ am­
plification as a prognostic factor. Allelic loss of chro­
mosome Ip was found in all patients with N-myc am­
plification, and thus it identified the same patients at
high risk as that, factor. However, allelic loss of chro­
mosome lp was also found in patients with a single 
copy of N-myc (i.e., without amplification), and it pre­
dicted their unfavorable outcome. For these patients 
the univariate hazard ratio associated with allelic' loss
of chromosome lp was 3.9 (95 percent confidence 
interval, 1.6 to 9.6; P = 0.003), and they had a three- 
year rate of event-free survival of 35± k) percent. 
Among patients with both allelic loss of chromosome 
Ip and N-myc amplification, the corresponding rate was
0 percent.
Prognostic Value of Allelic Loss of Chromosome 1p
Regardless of Age or Tumor Stage
To gain more insight into the effect of allelic loss of 
chromosome lp on clinical outcome we analyzed event- 
free survival according to chromosome lp status among 
patients of differing stages and ages. The predicted rate 
of event-free survival for three years among patients in 
stages I, II, and IVS was 83 ±6 percent, as compared 
with 30 ±7 percent among patients in stages III and IV 
(P = 0.002) (Fig. 2A). Among patients with allelic loss of 
chromosome lp, the rate of event-free survival lor three 
years was 12±7 percent, as compared with 75±6 per­
cent among those in whom no such loss was detectable
(P<0.00I) (Fig. 2B). Among patients with stage I, II, 
or IVS disease, loss of chromosome lp identified those 
in whom standard treatment was most likely to fail
9
(three-year event-free survival, 3-1 ± 15 percent) (Fig. 20), 
The remaining patients in these disease stages, who did 
not have allelic loss of chromosome lp, all survived for 
three years without events (PC0.00I). Among patients 
with stage III or IV disease, loss of chromosome lp de­
fined a very-high-risk group, none of whose members 
survived for three years free of events, whereas among 
those who did not have such loss the three-year event-
free survival was 53±10 percent (P<0.001) (Fig. 21)).
Among the 52 patients one year old or older, none of 
the 17 who had lp loss in their tumors survived without 
events for three years, whereas the rate of three-year 
event-free survival was 52 ±9 percent in the 35 who did 
not have lp loss (P<0.001). Among the 37 patients less 
than one year old, the three-year event-free survival in 
the 12 with allelic loss of lp was 32± 15 percent, as 
compared with 100 percent in the 25 without such loss
(PC0.001).
The group of patients with N-//m; amplification was 
a subgroup of the patients with lp loss. Therefore, the 
patients without N-myc amplification constituted a grouj 
in which loss of chromosome lp had additional prog­
nostic value. The clinical characteristics of these* two
)
groups with allelic loss ol chromosome lp differed, 
N-myc amplification occurred together with 1 p loss main­
ly in patients with stage III or IV disease (Hi ol’ 17 pa­
tients) and in patients one year old or older (13 of 17 
patients). Among the 72 patients without N-wjr ampli­
fication, 12 (17 percent) had allelic loss of chromosome 
lp. Three of these 12 patients had stage* IV tumors and
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Figure 2. Kaplan-Meier Curves for Event-free Survival.
The study population of patients with neuroblastoma is analyzed according to stage in Panel A and according to chromosome 1p 
status in Panel B. Patients with stage I, II, or IVS disease are analyzed according to chromosome 1p status in Panel C, and patients 
with stage III or IV disease are analyzed according to chromosome 1 p status in Panel D. Vertical bars show the 95 percent confidence 
intervals for three-year event-free survival, except for the group in Panel D with stage III or IV disease and allelic loss of chromosome
1p, for whom the bar shows two-year survival without events.
were one year old or older. The remaining' nine patients, 
who had lp loss but no N-//iyc amplification, had stage
I, II, or IVS neuroblastomas, and eight of these patients 
were less than one year old. This shows that among the 
patients without N-/wjr amplification, most of those at 
high risk who were identified on the basis of allelic loss 
of chromosome lp were under the age of one. year and 
had stage I, II, or IVS tumors.
D is c u s s io n
Our study found that allelic loss of chromosome lp 
is a powerful prognostic indicator in patients with neu­
roblastoma. Univariate testing showed that four genet­
ic variables (allelic loss of* chromosome lp, N-wyr am­
plification, extra copies of chromosome I7q, and a 
nearly diploid nuclear DNA content.) were significant 
predictors of unfavorable outcome. The prognostic val­
ue of N-wyf amplification in neuroblastoma is well es- 
lablishecL11,1:1 In this study, allelic loss of chromosome lp 
was found to be a better prognostic indicator than N-wytf 
amplification. The latter was present in a subgroup of 
patients whose tumors had allelic loss of chromosome 
Ip. Moreover, patients whose neuroblastomas had a sin­
gle copy of N-myc and allelic loss of chromosome lp 
were at high risk for an unfavorable outcome. The pres­
ence of extra copies of chromosome 17q and nearly dip­
loid nuclear DNA content were of only minor prognostic 
significance as compared with allelic loss of chromo­
some lp and N-wzyc amplification.
The main clinical value of allelic loss of chromosome 
Ip as a prognostic factor lies in its ability to detect pa­
tients at high risk among those who do not have 
amplification. For patients with stage I, II, or IVS dis­
ease, N-W)V’ amplification was a rare event and was not
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present in the majority of patients with an unfavorable 
outcome. Patients with stage I, II, or IVS disease who 
had lp loss (12 percent of the patients in this scries) 
were at a higher risk for recurrence than those who did 
not have such loss (three-year event-free survival, 34- 
percent vs. 100 percent). In patients such as the former, 
more aggressive therapy at diagnosis may be consid­
ered. Patients with stage I, II, or IVS disease without al­
lelic loss of chromosome lp (30 percent of the patients 
in this series) had an excellent prognosis (three-year 
event-free survival, 100 percent). In this group oi pa­
tients, therapy should be as minimal as possible and 
should be viewed in the light of possible late effects. 
Among patients in stages III and IV, additional patients 
at very high risk who did not have N-myc amplification 
were identified on the basis of lp loss. However, in this 
group the additional prognostic value of lp loss was 
limited, because most of the patients at very high risk 
had N-z/zyf amplification together with allelic loss of chro­
mosome lp. The current intensive multimodal therapy 
may be especially useful for patients with stage III or IV 
disease but no lp loss, whereas more innovative thera­
peutic approaches may be justified in patients with stage 
III and IV disease who have such loss.
The association between allelic loss of lp and out­
come has been described in three other studies. Fong et 
al.7 described five patients without N-myc amplification 
who had allelic loss of chromosome lp, three of whom 
remained disease-free for more than three years. Am- 
bros et al.2() studied 42 stage I and II neuroblastomas 
with single copies of N-myc. Among the 5 patients with 
lp loss, 3 had recurrences, as compared with 1 of the 
remaining 37 patients without such loss. Takeda et al.9 
described four patients with allelic loss of lp and no 
N-myc amplification who had a relatively short mean 
follow-up of 15 months and did not have events. In our 
series, the 12 patients with allelic loss of chromosome 
lp and a single copy of the gene had a relative
risk of recurrent disease of 3.9, with a three-year event- 
free survival of 35 percent. Taken together, these data 
indicate that allelic loss of chromosome lp identifies 
more patients who are likely to have an unfavorable 
outcome than does N-myt; amplification alone. Howev­
er, some patients whose tumors have allelic loss of 
chromosome lp and a single copy of the N-royc gene 
are long-term survivors. Thus, the principal advantage 
of using allelic loss of chromosome lp as a prognostic 
factor is in identifying high-risk patients among those 
with single copies of N-myc, the majority of whom have 
stage I, II, or IVS neuroblastomas.
We arc indebted to J. Groot-Looncn, K. Hahlen, H. Hey, R. Lip- 
pens, K. Moorman-Voestermans, Y. Meijer, N. Schoulen-van Mccter-
en, and M. van Wed for providing blood and tumor samples; to J.H. 
Bras for assistance with the histologic analyses; to A.J.M. de Cracn 
for assistance with the statistical analysis; and to J. Armour, 
A. Frischauf, M. Schwab, G, Vergnaud, the Japanese Cancer Re­
sources Bank, and the American Type Culture Collection for making 
DNA probes available to us.
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